Journal of Biotechnology & Biomaterials
Open Access

Abstract

Yeasts are amenable for the expression of heterologous proteins of therapeutic value originating from other eukaryotic organisms. Patent protection of Pichia pastoris based vectors entail payment of high license fees to the inventor. This triggered out effort to develop an alternative, cost effective system in Schizosaccharomyces pombe, which because of several molecular similarities with eukaryotes and whole genome sequenced is deemed to be potentially an ideal host for heterologous protein expression. In present work, we have developed an expression vector with strong promoter achieving higher yields of soluble protein than P. pastoris. Using this expression vector, we achieved consistently high level of bench scale expression of GFP, luciferase and Hepatitis B surface antigen (100-300 mg/l) which was not only 20-40 fold higher than that achieved with the known strong promoters of Schizosaccharomyces pombe but also over 10-fold higher than that of AOX promoter of Pichia pastoris. Thus our expression vector holds great potential for low cost production of therapeutic recombinant proteins.

Biography

Suchita Srivastava has completed her PhD from CSIR-CIMAP in 2014 and she is currently working as DBT-Research Associate under the mentorship of Dr. Jagmohan Singh at CSIR-IMTECH. She has published 14 research papers in reputed national and international journals and participated and presented her research work in national and international conferences. She is holding membership of 5 scientific bodies and she has also been the participant of First Science conclave and Nobel laureate Meet at IIIT, Allahabad.

Email: suchita.srivastava@gmail.com